How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review

Journal of Clinical Oncology

Volumn 19, Issue 3, 2001, Pages 870-880

  Kushner, B H ^a   Meyers, P A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; THIOTEPA; VINCRISTINE;

ADOLESCENT; ADULT; BONE MARROW METASTASIS; BONE MARROW TRANSPLANTATION; BONE METASTASIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; EWING SARCOMA; FEMALE; HUMAN; MALE; NEUROECTODERM TUMOR; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; WHOLE BODY RADIATION;

EID: 0035253384     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.3.870     Document Type: Review

References (63)

1. The Ewing family of tumors: Ewing's sarcoma and primitive neuroectodermal tumors
2. Very high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults
3. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
4. Treatment of peripheral neuroepithelioma in children and young adults
5. Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: Six months of intensive combined modality therapy without maintenance
6. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy
7. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma
8. Ifosfamide and etoposide plus vincristine, doxorubicin and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors
9. Ewing's sarcoma metastatic at diagnosis: Results and comparisons of two Intergroup Ewing's Sarcoma Studies
10. Long-term results from the first UKCCSG Ewing's Tumor Study (ET-1)
11. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study
12. Ewing's sarcoma and primitive neuroectodermal tumor in adults: Are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children?
13. Metastatic Ewing's sarcoma: Remission induction and survival
14. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone
15. Outcome in 43 children presenting with metastatic Ewing sarcoma: The St Jude Children's Research Hospital experience, 1962 to 1992
16. Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor with Ewing's-directed therapy
17. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: A feasibility study at St Jude Children's Research Hospital
18. Treatment results of Ewing's sarcoma with metastases at diagnosis: A retrospective analysis of 48 patients
19. Ewing's tumors with primary lung metastases: Survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients
20. Primary metastatic (stage IV) Ewing tumor: Survival analysis of 171 patients from the EICESS studies
21. The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours
22. Poor results in metastatic Ewing sarcomas (ES) treated according to the scheme of the Saint Jude 1978-1985 study: A study of the French Society of Pediatric Oncology
23. Metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone: Failure of new regimens to improve outcome
24. Malignant peripheral neuroectodermal tumors (MPNT) and extraosseous Ewing sarcoma (EES) in childhood and adolescent: Results of the German Cooperative Soft Tissue Sarcoma Studies CWS-81 +86
25. Induction chemotherapy (CT) followed by melphalan/etoposide/total body irradiation (MEL/E/TBI) and peripheral blood stem cell (PBSC) support for patients (pts) with newly diagnosed high-risk Ewing's sarcoma (ES)
26. High-risk Ewing's sarcoma: End-intensification using autologous bone marrow transplantation
27. Magna-field irradiation and autologous marrow rescue in the treatment of pediatric solid tumors
28. Secondary leukemia (SL) or myelodysplastic syndrome (MDS) following therapy for Ewing's sarcoma
29. High-dose cyclophosphamide: Adriamycin, and vincristine (HD-CAV) in children with recurrent solid tumor
30. A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: A report from the Australia and New Zealand Children's Cancer Study Group
31. Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas
32. The Pediatric Oncology Group (POG) experience in Ewings sarcoma of bone
33. Multimodal therapy for children and adolescents with Ewing sarcoma: Results of the first national Chilean trial (1986-1991)
34. Malignant peripheral neuroectodermal tumors: A retrospective analysis of 42 patients
35. Impact of megatherapy in children with high-risk Ewing's tumors in complete remission: A report from the EBMT Solid Tumor Registry
36. A multivariate and matched pair analysis on high-risk Ewing tumor (ET) patients treated with megatherapy (MGT) and stem cell reinfusion (SCR) in Europe
37. The role of megatherapy (MGT) followed by stem cell rescue (SCR) in high risk Ewing tumors (ET)
38. Place de la chimiothérapie à hautes doses suivie d'autogreffe médullaire dans le traitement des sarcomes d'Ewing métastatiques de l'enfant
39. Is treatment intensification by adding etoposide and carboplatin to fractionated total body irradiation and melphalan acceptable in children with solid tumors with respect to toxicity?
40. High-dose melphalan, etoposide ± carboplatin (MEC) combined with 12-gray fractionated total-body irradiation in children with generalized solid tumors
41. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma
42. Busulfan, melphalan and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-sarcoma-family tumors
43. Autologous stem cell transplantation for high-risk pediatric solid tumors
44. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma
45. Peripheral blood stem cells used to augment autologous bone marrow transplantation
46. Megatherapy in children with high-risk Ewing's sarcoma in first complete remission
47. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors
48. High-dose busulfan and cyclophosphamide with autologous bone marrow support in advanced malignancies in children: A phase II study
49. Consolidation with busulfan and melphalan followed by blood progenitor cell (BPC) graft in children and young adults with high risk Ewing sarcoma: A report of the French Society of Pediatric Oncology (SFOP)
50. Consolidation with busulfan and melphalan followed by hematopoietic stem-cell transplantation (SCT) in children with poor risk prognosis Ewing's sarcoma
51. Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue
52. High-dose melphalan ± total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor
53. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors
54. Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue: A feasibility study
55. High-risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors
56. Treatment of Ewing's sarcoma with high-dose melphalan and autologous bone marrow rescue
57. Treatment of Ewing's sarcoma with high-dose melphalan and autologous bone marrow rescue
58. High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and Ewing's sarcoma
59. High dose melphalan and autologous bone marrow transplantation for solid tumors of childhood
60. Myeloablative therapy, stem cell rescue and gene transfer in advanced Ewing tumors
61. In vitro chemosensitivity of two Ewing's sarcoma cell lines: Implication for autologous bone marrow transplantation
62. Immunomagnetic purging of Ewing's sarcoma from blood: Quantitation by real-time PCR